Non–Small-Cell Lung Cancer
The FDA has approved tepotinib for the treatment of adults with metastatic NSCLC with MET exon 14 skipping alterations.
True or false: Platinum-based chemotherapy demonstrated a longer overall survival than atezolizumab in NSCLC patients with high PD-L1 expression.
First-line lorlatinib, when compared to crizotinib, demonstrated longer PFS and a higher frequency of intracranial response in previously treated patients with ALK-positive NSCLC.
Multimodality therapy demonstrated higher OS when combined with neoadjuvant therapy in patients with stage IIB NSCLC.
Edward B. Garon MD, MS, engaged in a stimulating debate regarding the relevancy of angioinhibition in the management of NSCLC, particularly for EGFR-positive patients, at the virtual 2020…
At the virtual 2020 Personalized Therapies in Thoracic Oncology meeting, Jonathan Goldman, MD, provided an overview of how to manage patients with ALK-resistance in non-small-cell lung cancer (NSCLC).
In a session presented at the 2020 Personalized Therapies in Thoracic Oncology virtual meeting, Alexander Drilon PhD, Memorial Sloan Kettering Cancer Center, New York, shared insight on MET-dependent…
True or false: Moderate neutropenia levels predict improved OS in NSCLC after gem-carbo therapy.